Review paper
An update on drug development for the treatment of metabolic (dysfunction) associated fatty liver disease: Progress and opportunities
Abstract
Despite the rising health burden of metabolic (dysfunction) associated fatty liver disease (MAFLD), there are no approved pharmacotherapies for MAFLD currently. This situation led to a significant escalation in drug development and randomized controlled trials for MAFLD, particularly as novel information about its molecular pathogenesis unfolds. Currently, there are numerous investigational candidate drugs for MAFLD in various stages of clinical...
Paper Details
Title
An update on drug development for the treatment of metabolic (dysfunction) associated fatty liver disease: Progress and opportunities
Published Date
Oct 1, 2021
Volume
60
Pages
170 - 176
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History